Truist analyst Joon Lee lowered the firm’s price target on Arvinas (ARVN) to $21 from $65 and keeps a Buy rating on the shares as part of a broader research note on Biotech. The firm expects Arvinas to seek Vepdeg FDA approval but believes a label restricted to ESR1mut pts is likely for monotherapy, and Truist is updating its estimates to reflect a revised commercialization potential for Vepdeg resulting in peak sales of $1B vs. $1.8B consensus, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Promising Phase 1 Results and Favorable Safety Profile of ARV-102 Support Buy Rating for Arvinas Holding Company
- Arvinas Holding’s Innovative Approach and Promising Data Justify Buy Rating
- Promising Potential of Arvinas’ ARV-102 in Parkinson’s Treatment: A Buy Recommendation
- Arvinas price target lowered to $24 from $67 at Piper Sandler
- Promising Early Results and Positive Outlook for Arvinas’ ARV-102 Support Buy Rating